Focus: Pfizer is a diversified Big Pharma giant with 88,000 employees and $59.6B in FY2025 revenue, anchored by oncology, immunology, and vaccine franchises with strength in solid oral dosage forms.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
Hot — 896 jobs added in 30d
Net +248 (896 new, 648 removed). Aggressive expansion phase.
Pfizer offers scale, resources, and therapeutic depth attractive to mid-to-senior professionals seeking established R&D/Commercial environments, but job security is compromised by active restructuring and high revenue concentration risk.
Flagship kinase inhibitor representing 35% of company revenue; 73 trials demonstrate clinical depth; patent protection until 2037 provides revenue stability.
Help build intelligence for Pfizer
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pfizer's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rare disease blockbuster with $1.3B Part D spending; LOE in 2035 represents moderate future risk.
JAK inhibitor franchise asset with $586M annual Part D spending; patent cliff at 2034 requires pipeline replacement strategy.
CGRP antagonist with extended exclusivity to 2039; migraine indication shows steady adoption and lower generic erosion risk.
Receptor tyrosine kinase inhibitor with solid $467M revenue and patent protection to 2037; established oncology franchise player.
Immediate patent cliff (June 2026) indicates ongoing generic conversion; XELJANZ XR is preferred formulation with longer exclusivity.
BCR-ABL TKI with $199M revenue and patent protection to 2034; second-line CML asset with demonstrated imatinib-resistance coverage.
Immediate patent cliff (Dec 2026) represents $118M imminent revenue erosion; first major patent loss on the horizon.
Tyrosine kinase inhibitor with extended patent protection to 2038; part of broad oncology franchise targeting HER2+ disease.
1497 discontinued, 535 duplicate formulations not shown
+49 more products with revenue data
+2 more
Is Pfizer (NYSE:PFE) Valuation Getting Ahead of Its Pipeline? - Kalkine Media
Is Pfizer (NYSE:PFE) Valuation Getting Ahead of Its Pipeline? Kalkine Media
Medicus Pharma advances SkinJect and Pfizer par... - Pluang
Medicus Pharma advances SkinJect and Pfizer par... Pluang
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI - Proactive financial news
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI Proactive financial news
Pfizer (PFE) Stock Looks Fully Priced Despite Pipeline Optimism - simplywall.st
Pfizer (PFE) Stock Looks Fully Priced Despite Pipeline Optimism simplywall.st
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Inside the deal: How a Montco biotech secured a Pfizer drug candidate The Business Journals
Why Pfizer (NYSE:PFE) Is Standing Out As Defensive Healthcare Draws Notice - Kalkine Media
Why Pfizer (NYSE:PFE) Is Standing Out As Defensive Healthcare Draws Notice Kalkine Media
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.
Plain language summary looking at the impact of drug management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the USA.
+270 more products
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
+2 more
Source: state DOL filings, aggregated via Big Local News
Active WARN filings across manufacturing and R&D footprint (Groton, Everett, Tampa, Bothell) signal ongoing reorganization; job security uncertain without clarity on business unit prioritization.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo